

Clinical Policy: Erwinia Asparaginase (Erwinaze)

Reference Number: LA.PHAR.301

Effective Date:

Last Review Date: 03.21

Line of Business: Medicaid

Coding Implications

Revision Log

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Asparaginase *Erwinia chrysanthemi* (Erwinaze®) is an asparagine specific enzyme.

FDA Approved Indication(s)

Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to *E. coli*-derived asparaginase.

Policy/Criteria

Prior authorization is required. Provider must submit documentation (including such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections that Erwinaze is medically necessary when the following criteria are met:

I. Initial Approval Criteria

A. Acute Lymphoblastic Leukemia (must meet all):

1. Diagnosis of ALL;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Prescribed as a component of a multi-agent chemotherapeutic regimen;
4. Member meets (a or b):
 - a. Member has developed hypersensitivity to an *E. coli* derived asparaginase product (Elspar® - off-market) or pegaspargase (Oncaspar®);
 - b. Age ≥ 65 years and Erwinaze is prescribed as combination induction therapy;
5. Request meets one of the following (a or b):*
 - a. Dose should not exceed 25,000 International Units per m² administered three times per week;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

*Prescribed regimen must be FDA-approved or recommended by NCCN.

Approval duration: 3 months

B. Other diagnoses/indications

1. Refer to LA.PMN.53 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. Acute Lymphoblastic Leukemia (must meet all):

1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Erwinaze for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose should not exceed 25,000 International Units per m² administered three times per week;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Louisiana Healthcare Connections benefit and documentation supports positive response to therapy.
Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): LA.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – LA.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ALL: acute lymphoblastic leukemia

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may require prior authorization.

<u>Drug Name</u>	<u>Dosing Regimen</u>	<u>Dose Limit/ Maximum Dose</u>
<u>Oncaspar (pegaspargase)</u>	<ul style="list-style-type: none"> • <u>Administered IM or IV no more frequently than every 14 days.</u> • <u>Patients ages 21 years and younger: 2,500 International Units/m².</u> • <u>Patients ages over 21 years: 2,000 International Units/m².</u> 	<u>Varies</u>

CLINICAL POLICY

Erwinia Asparaginase

<u>Drug Name</u>	<u>Dosing Regimen</u>	<u>Dose Limit/ Maximum Dose</u>
	<ul style="list-style-type: none"> For IM administration, limit the volume at a single injection site to 2 mL; if greater than 2 mL, use multiple injection sites. For IV administration, give over a period of 1 to 2 hours in 100 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP through an infusion that is already running. Do not administer Oncaspar if drug has been frozen, stored at room temperature for more than 48 hours, or shaken or vigorously agitated. 	

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): History of 1) serious hypersensitivity reactions to Erwinaze, including anaphylaxis, 2) serious pancreatitis with prior L-asparaginase therapy, 3) serious thrombosis with prior L-asparaginase therapy, 4) serious hemorrhagic events with prior L-asparaginase therapy.
- Boxed warning(s): None reported.

V. Dosage and Administration

<u>Indication</u>	<u>Dosing Regimen</u>	<u>Maximum Dose</u>
<u>ALL</u>	<u>To substitute for pegaspargase: the recommended dose for each planned dose of pegaspargase is 25,000 International Units/m² administered IM or IV TIW (Monday/Wednesday/Friday) for six doses.</u>	<u>25,000 IU/m²/dose</u>

VI. Product Availability

10,000 International Units lyophilized powder per vial

VII. References

- Erwinaze Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; December 2019. Available at <https://pp.jazzpharma.com/pi/erwinaze.en.USPI.pdf>. Accessed October 12, 2020.
- Oncaspar Prescribing Information. Gaithersburg, MD: Sigma-Tau Pharmaceuticals, Inc.; August 2019. Available at https://www.oncaspar.com/prescribing_information.pdf. Accessed October 12, 2020.
- National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at www.nccn.org. Accessed October 12, 2020.

CLINICAL POLICY

Erwinia Asparaginase

4. Acute Lymphoblastic Leukemia Version 1.2020. National Comprehensive Cancer Network Guidelines. Available at www.nccn.org. Accessed October 12, 2020.
5. Pediatric Acute Lymphoblastic Leukemia Version 1.2021. National Comprehensive Cancer Network Guidelines. Available at www.nccn.org. Accessed October 12, 2019.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<u>HCPCS Codes</u>	<u>Description</u>
<u>J9019</u>	<u>Injection, asparaginase, (Erwinaze), 1,000 IU</u>

<u>Reviews, Revisions, and Approvals</u>	<u>Date</u>
<u>Converted corporate to local policy</u>	<u>03.2021</u>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a

CLINICAL POLICY

Erwinia Asparaginase

discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2020 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.